Online inquiry

IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ739MR)

This product GTTS-WQ739MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ739MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14708MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SEG101
GTTS-WQ1413MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACA125
GTTS-WQ823MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ10646MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-3819253
GTTS-WQ15427MR IVTScrip™ mRNA-Anti-LAG3, TSR-033(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA TSR-033
GTTS-WQ6729MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA DS 1024
GTTS-WQ178MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ7702MR IVTScrip™ mRNA-Anti-ERBB2, GEXMab73(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GEXMab73
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW